Taxifolin (Dihydroquercetin): A Comprehensive Reference
1. Identity and Chemical Characterization
1.1 Names and Classification
Taxifolin (3,5,7,3′,4′-pentahydroxy flavanone), a naturally occurring flavonoid also known as dihydroquercetin, has the molecular formula C15H12O7, a molecular weight of 304.25 g/mol, and the systematic IUPAC name (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydrochromen-4-one. It belongs to the flavanonol subclass of flavonoids, which are part of the broader group of polyphenolic compounds.
The C15 framework consists of two benzene rings (A and B) joined by a heterocyclic ring (C). The antioxidant properties of taxifolin are supported by five hydroxyl groups placed at positions 3, 5, 7, 3′, and 4′ that enable effective free radical scavenging. Taxifolin contains two stereocenters at positions 2 and 3 of its C-ring, which produces multiple stereoisomeric forms.
Taxifolin has two stereocenters on the C-ring, as opposed to quercetin, which has none. For example, (+)-taxifolin has (2R,3R)-configuration, making it one out of four stereoisomers that comprise two pairs of enantiomers. This stereochemical complexity differentiates taxifolin from its structural analogue quercetin and has implications for its biological activity.
1.2 Natural Sources and Botanical Origins
Taxifolin is a naturally occurring flavonoid found in a variety of plant species such as milk thistle (Silybum marianum), onions (Allium cepa), Douglas fir bark (Pseudotsuga taxifolia), and French maritime pine bark (Pinus pinaster). It was first isolated from Douglas fir bark (Pseudotsuga taxifolia (Lindl.) Britton).
Taxifolin has been found in different gymnosperms including Larix sibirica (Siberian larch), Larix gmelini (Dahurian larch), Larix decidua (European larch), Larix kaempferi (Japanese larch), Pseudotsuga taxifolia (Douglas fir bark), Picea abies (European spruce), Chamaecyparis obtusa (blunt-leaved cypress), Pinus silvestris, Pinus roxburghii, Pinus sibirica, Cedrus deodara, Juniperus communis, and Taxus chinensis.
Taxifolin is also found in non-glutinous rice boiled with adzuki bean (adzuki-meshi), and in vinegars aged in cherry wood. Specifically, taxifolin is found in plant-based foods like fruit, vegetables, wine, tea, and cocoa.
It is also found in the silymarin extract from milk thistle seeds. It is used in various commercial preparations like Legalon™, Pycnogenol®, and Venoruton®.
1.3 Biosynthesis
Taxifolin and related compounds are biosynthesized via the phenylpropanoid pathway, and most of the biosynthetic steps have been functionally characterized. The knowledge gained through detailed investigation of their biosynthesis has provided the foundation for the reconstruction of biosynthetic pathways.
1.4 Common Forms and Preparations
The commercially available taxifolin-rich extract used in European food ingredient applications is a water–ethanol extract from the wood of Dahurian Larch and contains a minimum of 90% taxifolin. In practice, it is rarely used singly, but is often used in preparations such as silymarin (Legalon™) along with silybin A, silybin B, isosilybin A, and other compounds. Taxifolin is marketed as a dietary supplement in capsule, tablet, and powder form, and is also incorporated into functional foods, beverages, and cosmetic products.
2. Discovery and Historical Context
In the late 1940s, the Oregon Forest Products Laboratory (USA) began investigating the chemical composition of the bark of western pine trees. One of the first species to be thoroughly studied was Douglas fir bark, where a bioflavonoid with a very powerful antioxidant effect was found and identified as taxifolin, also known as dihydroquercetin (Pew, John C., 1947).
For a long time it was believed that dihydroquercetin was found only in expensive raw materials such as citrus fruits, grape seeds, Japanese Sophora, rose petals, and stems of Ginkgo biloba. The level of development of laboratory and industrial techniques of the twentieth century did not allow obtaining bioflavonoids, including dihydroquercetin, in large quantities, which put a barrier to their wide implementation in preventive and clinical medicine.
3. Traditional and Historical Use
The silymarin complex consisting of four flavonolignans (silychristin, silydianin, silibinin, and taxifolin) has been used from ancient times in both traditional European and Asian medicine for liver disorders treatment.
The medicinal use of taxifolin can be traced back centuries, particularly in Russia and parts of Asia, where decoctions and extracts from larch have been traditionally employed to support overall health, promote longevity, and boost resilience to environmental stresses. Folk healers valued taxifolin-rich preparations for their reputed benefits in addressing respiratory ailments, circulatory problems, and inflammatory conditions. These remedies were believed to fortify the body against infections, aid in wound healing, and alleviate symptoms of cold and flu.
Taxifolin contained in Siberian larch has P-vitamin and antioxidant activity and is one of the most active and stable antioxidants. The pharmacological properties of dihydroquercetin are well studied by the Research Institute of Pharmacology of the Siberian Branch of the Russian Academy of Medical Sciences (Tomsk), the Moscow Medical Academy. The substance was included in the register of medicines in Russia in 2002.
In Korea, Rhododendron mucronulatum — another taxifolin-containing plant — is distributed across parts of China, Japan, and all over Korea. Its roots have been used extensively in oriental traditional medicine as remedies for fever, dysuria, and as a tonic in Korea and China.
It is important to note that these historical uses were attributed to whole plant extracts, not to isolated taxifolin specifically. Scientific attribution of observed traditional benefits to the taxifolin constituent alone requires separate evidence.
4. Key Constituents, Active Compounds, and Mechanisms of Action
4.1 Antioxidant Mechanisms
The flavonoid taxifolin, also known as dihydroquercetin, has similar pharmacological effects to other flavonoids. Its antioxidant capacity, however, is superior to that of common flavonoids. The antioxidant properties of taxifolin are supported by five hydroxyl groups placed at positions 3, 5, 7, 3′, and 4′ that enable effective free radical scavenging.
Taxifolin activates Nrf2 to induce the expression of HO-1, which plays a role in suppressing oxidative stress and inflammation. This regulation leads to a reduction in pro-inflammatory cytokines such as TNF-α and IL-6 and decreases markers of oxidative stress.
Formation of free radicals in mitochondria plays a key role in the development of apoptosis, which includes formation of superoxide by the respiratory chain, and chain lipid peroxidation resulting in cytochrome c release from mitochondria and initiation of the apoptotic cascade. In work studying the effect of taxifolin on these reactions, peroxidase activity of the complex of cytochrome c with dioleyl cardiolipin decreased by 50% with taxifolin at concentrations of 0.7 μM.
Dihydroquercetin plays an important role in recirculating vitamin C throughout the body and also enables vitamin C to last longer in the body.
4.2 Anti-Inflammatory Mechanisms
Taxifolin effectively scavenges reactive oxygen species (ROS), enhances antioxidant enzymes, and inhibits inflammatory responses through the NF-κB and PI3K/Akt pathways.
There is increasing evidence that Matrix metalloproteinase-10 (MMP-10) is involved in the inflammatory response. In asthma biopsies, MMP-10 expression was elevated in epithelial cells as well as in subepithelial inflammatory cells and resident cells. Airway remodeling and inflammation are associated with submucosal eosinophilia, in which MMP-10 may have an influential role. Taxifolin inhibits the expression of MMP-10 by blocking the Wnt/β-catenin pathway, improving inflammatory damage to human bronchial epithelial cells.
4.3 Cardiovascular Mechanisms
Taxifolin contributes to its cardioprotective effects through key mechanisms such as modulation of pathways such as PI3K/AKT and JAK2/STAT3, inhibition of NADPH oxidase, and modulation of nitric oxide production.
Taxifolin has been shown to inhibit platelet aggregation induced by various agonists, such as ADP, collagen, thrombin, U46619, and convulxin. Moreover, it also limited platelet adhesion to collagen and the synthesis of thromboxane A2 (TXA2).
Taxifolin attenuates liver injury in a mouse model of CCl4-induced acute liver injury by reducing oxidative stress through activation of antioxidant enzymes and inhibiting inflammatory responses in hepatocytes. Specifically, taxifolin maintained glutathione levels, reduced the accumulation of malondialdehyde, and prevented damage to cell membranes.
4.4 Anticancer Mechanisms
Taxifolin effectively scavenges ROS, enhances antioxidant enzymes, and inhibits inflammatory responses through the NF-κB and PI3K/Akt pathways. It protects the liver by reducing oxidative stress and apoptosis, while also demonstrating anticancer effects through cell cycle arrest and tumor suppression.
This effect of taxifolin is significant for the suppression of cell survival signals and the induction of apoptosis. Results in hepatocellular carcinoma models (HepG2 and Huh7 cells) depicted attenuation in mRNA and protein expression levels of Hif1-α, VEGF, and Akt upon taxifolin treatment, suggesting taxifolin can be a viable option for curbing cell survival and angiogenesis in hepatic carcinoma.
Taxifolin is not mutagenic and is less toxic than the related compound quercetin. It acts as a potential chemopreventive agent by regulating genes via an ARE-dependent mechanism.
4.5 Neuroprotective Mechanisms
Taxifolin is a bioactive catechol-type flavonoid that exhibits pleiotropic effects including anti-oxidant and anti-glycation activities. Researchers have demonstrated that taxifolin inhibits Aβ fibril formation in vitro and have further shown that it improves cerebral blood flow, facilitating Aβ clearance in the brain and suppressing cognitive decline in a mouse model of cerebral amyloid angiopathy (CAA).
In vitro, taxifolin inhibited the aggregation of amyloid-β1–40, a major component of vascular amyloid-β deposits; in vivo, it reduced the levels of amyloid-β oligomers in the brain, with a concomitant increase in the levels of amyloid-β1–40 in circulation. This suggested that taxifolin could facilitate amyloid-β clearance from the brain, perhaps through the intramural periarterial drainage (IPAD) system, a vascular-mediated amyloid-β elimination system — potentially maintaining vascular integrity, alleviating amyloid-β deposits, and preventing cognitive dysfunction.
5. Scientific Evidence by Health Area
5.1 Cardiovascular Health
Through its antioxidant and anti-inflammatory activities, taxifolin has shown significant therapeutic potential in cardiovascular diseases such as atherosclerosis, myocardial ischemia, and diabetic cardiomyopathy. However, the bulk of this evidence comes from preclinical (animal and cell culture) studies. Through its antioxidant and anti-inflammatory activities, taxifolin has shown significant therapeutic potential in cardiovascular diseases such as atherosclerosis, myocardial ischemia, and diabetic cardiomyopathy. Reviews highlight cardioprotective effects in preclinical models of atherosclerosis, ischemia/reperfusion injury, and diabetic cardiomyopathy.
Taxifolin has shown cardiovascular benefits, but its antihypertensive mechanisms remain poorly defined. One study aimed to comprehensively elucidate the molecular mechanisms underlying taxifolin's blood pressure-lowering effects by integrating network pharmacology, molecular docking, ex vivo functional studies, and in vivo validation. In that study, in vivo spontaneously hypertensive rats (SHRs) received oral taxifolin at 15, 30, or 60 mg/kg once daily for 28 days, with propranolol (80 mg/kg) serving as the positive control. Taxifolin produced robust vasorelaxation in endothelium-intact aortic rings (Rmax ≈ 121%), falling to approximately 72% after endothelial denudation. This work was conducted in animal models rather than humans.
Network pharmacology analysis suggested that taxifolin may exert antiplatelet effects through key targets involved in platelet aggregation and thrombus formation, such as MAPK1, AKT1, SRC, PIK3R1, and MAPK8. Taxifolin modulates platelet-related MAPK and PI3K/Akt signaling pathways, thereby inhibiting platelet aggregation, granule release, adhesion, spreading, and clot retraction. In animal models, taxifolin showed promising results in preventing pulmonary embolism and arterial thrombosis. These findings require confirmation in human clinical trials before cardiovascular clinical recommendations can be made.
5.2 Hepatoprotection (Liver Health)
Taxifolin's antioxidant and anti-inflammatory properties underpin its ability to counteract oxidative stress and inflammation, which are two pivotal mechanisms in the pathogenesis of liver diseases.
Taxifolin extracted from L. olgensis roots was shown to attenuate CCl4-induced liver fibrosis by regulating the PI3K/AKT/mTOR and TGF-β1/Smads signaling pathways. This was demonstrated in vivo with mice and suggested that taxifolin might be an efficient hepatoprotective agent.
The protective effects of taxifolin were evaluated in mice with induced hepatic encephalopathy, and it was found that taxifolin contributed to alleviating the symptoms by suppressing inflammation and oxidative stress in the liver and brain. The study confirmed that taxifolin alleviated hepatic encephalopathy by maintaining the integrity of the blood–brain barrier and reducing neuroinflammation.
In compound activity data from a liver protection assay against hepatitis C virus infection, taxifolin showed strong activity in four out of five assays, with liver protection observed at lower doses compared to other compounds. Taxifolin was demonstrated to inhibit viral infection, virus-induced oxidative stress, NF-κB-dependent transcription, and TCR-mediated proliferation. These findings are derived from cell-based and animal models; controlled human studies on taxifolin's hepatoprotective effects remain limited.
5.3 Neurodegenerative Diseases
Cerebral amyloid angiopathy (CAA) is characterized by the accumulation of β-amyloid (Aβ) in the walls of cerebral vessels, leading to complications such as intracerebral hemorrhage, convexity subarachnoid hemorrhage, and cerebral microinfarcts. Patients with CAA-related intracerebral hemorrhage are more likely to develop dementia and strokes. Several pathological investigations have demonstrated that more than 90% of Alzheimer's disease patients have concomitant CAA, suggesting common pathogenic mechanisms.
Taxifolin suppresses Aβ production, fibril formation, and neuroinflammation in the brain. It also ameliorates cerebrovascular dysfunction. Furthermore, taxifolin beneficially affects certain metabolic diseases with a high risk for neurodegenerative diseases and their complications. These direct and indirect effects of taxifolin would contribute to preventing and/or treating Aβ-associated cognitive dysfunction including CAA and Alzheimer's disease. These conclusions are primarily based on in vitro and animal (transgenic mouse) experiments.
Taxifolin, a natural bioactive flavonoid, shows pleiotropic neuroprotective effects with inhibition of Aβ aggregation, production, and glycation, anti-inflammatory effects, and amelioration of the waste clearance system. Researchers hypothesized that taxifolin intake is associated with the suppression of cognitive deterioration. To investigate associations between taxifolin intake and cognitive changes, they retrospectively identified patients who orally took taxifolin at 300 mg/day and regularly underwent Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog) and Montreal Cognitive Assessment (MoCA) tests, comparing the temporal changes in scores between the non-treatment (pre-taxifolin) period (180 ± 100 days) and following treatment (on-taxifolin) period (180 ± 100 days) from June 2020 to November 2021. This retrospective observational study, while notable for using a 300 mg/day oral dose, has significant limitations: it lacks a control group, is retrospective in design, and does not permit causal inference. Prospective randomized controlled trials in humans are still needed.
Some studies suggest that taxifolin is limited in its ability to cross the blood–brain barrier (BBB), limiting its effectiveness against amyloid-β aggregation in the brain. This is a key pharmacological challenge for its neurological applications.
5.4 Cancer (Preclinical Evidence)
Taxifolin showed promising pharmacological activities in the management of inflammation, tumors, microbial infections, oxidative stress, cardiovascular, and liver disorders. The anti-cancer activity was more prominent than other activities evaluated using different in vitro and in vivo models.
Taxifolin significantly inhibited the growth of primary tumors and reduced lung metastases of breast cancer in a 4T1 xenograft mouse model. However, excessive expression of adenovirus to β-catenin diminishes these beneficial effects. Taxifolin is expected to be used as a promising drug for the clinical treatment of highly aggressive breast cancer.
The expression of SOS1, a key regulator of the Ras pathway, is highly elevated in African American (AA) breast cancer patients. Taxifolin inhibited signal transduction of SOS1 by blocking the interaction between SOS1 and Grb2, demonstrating that taxifolin could be effective in combating SOS1-driven tumor progression.
Taxifolin has shown the ability to inhibit ovarian cancer cell growth in a dose-dependent manner. However, in this same study, taxifolin was the least effective flavonoid in the inhibition of VEGF expression.
Strength of evidence: To develop a medicine for human usage, more study on pharmacokinetic profile, profound molecular mechanisms, and drug safety criteria should be conducted utilizing well-designed randomized clinical trials. All anticancer findings reported for taxifolin to date are preclinical (cell culture and animal models). No human clinical trials have been published establishing taxifolin as an anticancer agent.
5.5 Metabolic and Diabetic Conditions
Taxifolin is known for many beneficial effects, such as improvement of microcirculation, hepatoprotective effects, anti-viral activity, and prevention of diabetic nephropathy as well as diabetic cardiomyopathy. These effects have been documented primarily in in vitro and animal models.
Recent studies have shown that taxifolin can affect glucose metabolism by modulating sodium–glucose transporter (SGLT) expression, potentially enhancing glycemic regulation.
Despite encouraging preclinical data, clinical studies evaluating taxifolin's antidiabetic efficacy remain lacking. Future clinical trials are essential to confirm its therapeutic potential and establish its role in diabetes management.
5.6 Respiratory Health
Taxifolin suppresses the inflammation and mucus formation induced by TNF-α. Taxifolin decreases MMP10 expression to inhibit human bronchial epithelial cells injury caused by TNF-α. All results imply that taxifolin ameliorates inflammatory damage in human bronchial epithelial cells induced by TNF-α due to the inhibition of MMP10 expression, possibly by blocking the Wnt/β-catenin pathway. The study demonstrates that taxifolin has potential effects on therapy of asthma. Future experimental in vivo studies of asthma will be required for further exploration of the effects and mechanism.
For cisplatin-induced pulmonary oxidative damage in male albino Wistar rats, taxifolin gives full play to its antioxidant properties, providing protection against oxidative stress in the lungs by inhibiting the increase in oxidant parameters and the reduction of antioxidants. These findings are from animal studies; there is no published human clinical evidence for taxifolin in respiratory disease management.
5.7 Antimicrobial Activity
In vitro cytotoxicity assays conducted on human epithelial (HEK293) and hepatic (HepG2) cell lines have confirmed its safety at concentrations effective against bacterial pathogens. Taxifolin also exhibits antioxidant and anti-inflammatory properties, which may confer additional protective effects to host tissues during bacterial infection. Its selectivity index, the ratio of cytotoxic to antimicrobial concentrations, further supports its potential for clinical use.
Dihydroquercetin from L. sibirica was noted to inhibit coxsackievirus B4 in preclinical research. Human clinical data confirming antimicrobial or antiviral efficacy are not currently available.
6. Body Systems Associated with Taxifolin
- Cardiovascular system: Taxifolin prevents atherosclerosis by inhibiting lipid peroxidation. It has also been studied for effects on endothelial function, platelet aggregation, and blood pressure regulation.
- Hepatic (liver) system: It has been shown to extend synergistic protection against certain life-threatening diseases of aging including cardiovascular, neurological, and diabetic disorders. Anti-fibrotic and liver-protective mechanisms have been documented preclinically.
- Nervous system: In the central nervous system, taxifolin has been demonstrated to inhibit Aβ fibril formation. Neuroprotection against amyloid-related pathology has been the focus of several animal and early observational studies.
- Immune system: Taxifolin was demonstrated to inhibit viral infection, virus-induced oxidative stress, NF-κB-dependent transcription, and TCR-mediated proliferation.
- Musculoskeletal system: Taxifolin has anti-inflammation activity, anti-viral activity, anti-tumor activity, and protective activity against postmenopausal osteoporosis. These effects remain at the preclinical stage.
- Integumentary (skin/hair): It was confirmed that a representative factor for promoting hair growth, IGF-1, was significantly increased, and that TGF-β1, a representative biomarker for hair loss, was significantly reduced with taxifolin treatment. These results suggest that taxifolin is a potential treatment for hair loss and a hair growth enhancer. This evidence derives from cell-based studies.
7. Dosage Forms and Dosages Reported in Studies
Taxifolin is commercially available in several dosage forms. The following dosages are reported specifically as used in cited research and regulatory contexts:
- In a retrospective observational study of patients with mild cognitive impairment or mild dementia, participants orally took taxifolin at 300 mg/day and were monitored with cognitive assessments over approximately 180-day periods.
- In a spontaneously hypertensive rat in vivo study, oral taxifolin was administered at 15, 30, or 60 mg/kg once daily for 28 days.
- In rat pharmacokinetic studies, taxifolin was administered intravenously or orally at the same dose of 15 mg/kg, and an oral nanodispersion formulation was also evaluated at the same dose.
- In a subchronic rat toxicity study performed in accordance with OECD standards, the highest dose tested, 1,500 mg/kg body weight, was considered to be the No Observed Adverse Effect Level (NOAEL).
- In 2016, the EFSA NDA Panel adopted a Scientific Opinion on the safety of taxifolin-rich extract from Dahurian Larch (Larix gmelinii) as a novel food ingredient in non-alcoholic beverages, yogurts, chocolate confectionery, and food supplements. The approved food ingredient applications specified use levels consistent with a dietary supplement context.
No universally established human therapeutic dose has been confirmed through large-scale randomized controlled trials. Dosages cited above are from individual studies and should be interpreted accordingly.
8. Bioavailability and Pharmacokinetics
Taxifolin still has some deficiencies such as poor stability, permeability, and low bioavailability, which limit its use. In vitro forced degradation tests and in silico stability predictions showed that taxifolin was extremely unstable under alkaline hydrolysis, and that the alkaline degradation product was a dimer of taxifolin.
The absolute bioavailability of taxifolin was calculated as 0.75% for a taxifolin nanodispersion formulation and 0.49% for taxifolin in its conventional form, respectively, in rat pharmacokinetic studies. These figures are from animal studies and may not directly translate to human bioavailability.
Pharmacokinetics of taxifolin has been investigated in scientific research and revealed that taxifolin had nonlinear pharmacokinetics in rats in the dose range of 10–50 mg/kg after single oral administration. Biologically active taxifolin metabolites such as aromadendrin and luteolin were also found in plasma samples.
Due to the poor stability, permeability, and low bioavailability of taxifolin, its application should consider loading into an appropriate drug delivery system and focusing on its metabolites and biotransformation in humans. Various enhanced delivery approaches have been explored, including inclusion complexes with different carriers to achieve appropriate water solubility and high stability, water-soluble polymer and surfactant nano-dispersions, and other taxifolin-loaded nanocarriers.
9. Safety Considerations and Known Interactions
9.1 General Safety Profile
A critical advantage of taxifolin is its low toxicity to mammalian cells, making it a favorable candidate for therapeutic development. In vitro cytotoxicity assays conducted on human epithelial (HEK293) and hepatic (HepG2) cell lines have confirmed its safety at concentrations effective against bacterial pathogens.
Taxifolin is not mutagenic and is less toxic than the related compound quercetin.
The EFSA Panel on Dietetic Products, Nutrition and Allergies considered that the taxifolin-rich extract is sufficiently characterised and that its compositional data and specifications do not raise safety concerns. The Panel considered that the data on genotoxicity do not raise concern. In a subchronic rat study performed in accordance with OECD standards, the highest dose tested (1,500 mg/kg body weight) was considered to be the NOAEL.
The EFSA Panel concluded that the novel food taxifolin-rich extract from Dahurian Larch is safe under the proposed conditions of use.
9.2 Antiplatelet Effects and Potential Bleeding Risk
Taxifolin inhibits platelet aggregation induced by various agonists, such as ADP, collagen, thrombin, U46619, and convulxin. Moreover, it also limits platelet adhesion to collagen and the synthesis of TXA2. This pharmacological activity raises a potential concern when taxifolin is co-administered with anticoagulants or antiplatelet drugs. In animal models, taxifolin showed promising results in preventing pulmonary embolism and arterial thrombosis; importantly, taxifolin did not cause significant side effects in these models. However, the additive effects on platelet function with existing anticoagulant or antiplatelet therapy in humans have not been systematically evaluated in clinical trials.
9.3 Limitations of Clinical Evidence and Research Gaps
Taxifolin has various pharmacological activities and significant therapeutic potential for the human body. In spite of this, most trials have been conducted at the cellular and animal level, revealing only the benefits of preclinical studies, while clinical trials have not been conducted so far.
A multi-targeted, non-specific effect of taxifolin may result in ambiguous or even contradictory biological effects. To develop a drug for human use, it is recommended that further research be conducted on the molecular mechanisms involved and the safety profile using well-designed randomized trials.
Further research on the pharmacokinetics, in-depth molecular mechanisms, and safety profile using well-designed randomized clinical studies are suggested to develop a drug for human use.
Taxifolin-rich extracts from Dahurian Larch (L. gmelinii) are a novel food ingredient in non-alcoholic beverages, yogurts, chocolate confectionery, and food supplements, and are reported to be safe within the context of that EFSA opinion.
References
Go back